494 related articles for article (PubMed ID: 32188379)
1. Nanomedicines in Diagnosis and Treatment of Cancer: An Update.
Haider N; Fatima S; Taha M; Rizwanullah M; Firdous J; Ahmad R; Mazhar F; Khan MA
Curr Pharm Des; 2020; 26(11):1216-1231. PubMed ID: 32188379
[TBL] [Abstract][Full Text] [Related]
2. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
5. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.
Cheng Y; Zhao L; Li Y; Xu T
Chem Soc Rev; 2011 May; 40(5):2673-703. PubMed ID: 21286593
[TBL] [Abstract][Full Text] [Related]
6. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
[TBL] [Abstract][Full Text] [Related]
7. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
8. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
Tracey SR; Smyth P; Barelle CJ; Scott CJ
Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
[TBL] [Abstract][Full Text] [Related]
9. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.
Sajja HK; East MP; Mao H; Wang YA; Nie S; Yang L
Curr Drug Discov Technol; 2009 Mar; 6(1):43-51. PubMed ID: 19275541
[TBL] [Abstract][Full Text] [Related]
10. Surface engineered multifunctional nano-systems for localised drug delivery against thyroid cancer: A review of current practices.
Zhang Y; Tang N; Zhou H; Zhu Y
Biomed Pharmacother; 2024 Jul; 176():116840. PubMed ID: 38820975
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles.
Liu Y; Miyoshi H; Nakamura M
Int J Cancer; 2007 Jun; 120(12):2527-37. PubMed ID: 17390371
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
14. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
15. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy.
Raj S; Khurana S; Choudhari R; Kesari KK; Kamal MA; Garg N; Ruokolainen J; Das BC; Kumar D
Semin Cancer Biol; 2021 Feb; 69():166-177. PubMed ID: 31715247
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles for Cancer Targeting: Current and Future Directions.
Swain S; Sahu PK; Beg S; Babu SM
Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485
[TBL] [Abstract][Full Text] [Related]
17. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
18. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
19. Actively Targeted Nanoparticles for Drug Delivery to Tumor.
Bi Y; Hao F; Yan G; Teng L; Lee RJ; Xie J
Curr Drug Metab; 2016; 17(8):763-782. PubMed ID: 27335116
[TBL] [Abstract][Full Text] [Related]
20. Improved Targeting of Cancers with Nanotherapeutics.
Foster C; Watson A; Kaplinsky J; Kamaly N
Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
